SK Biopharmaceuticals leads the way in biotech innovation with groundbreaking drug research, development, and commercialization worldwide.

We have independently developed cenobamate, an anti-seizure medication, from its initial discovery through clinical studies to FDA approval and successful commercialization.

SK Biopharmaceuticals is the only Korean biotech to have launched this FDA approved drug in the U.S. through its own sales network. The company also discovered solriamfetol, an FDA approved treatment for sleep disorder, and commercialized through partnership.

Breaking Barriers in Epilepsy Treatment

Cenobamate has forayed into advanced and emerging regions - North America, Europe, Asia, Central and South America, and the Middle East and North Africa. SK Biopharmaceuticals is conducting Phase 3 trials of cenobamate in Asian countries, aiming to further bring this revolutionary treatment to patients in these markets.

Taking the leap

On the back of the global success of cenobamate, SK Biopharmaceuticals is set to become a true leader in biotech.

We're expanding beyond the central nervous system, and venturing into three exciting and emerging therapeutic modalities: Targeted Protein Degradation, Radiopharmaceutical Therapy, and Cell & Gene Therapy. This brings us one step closer to becoming a leading “Big Biotech.”